Aveo Oncology and Bristol Myers Squibb are collaborating on a phase III clinical trial to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is partnering with the GO2 Foundation for Lung Cancer in a study—together with Vanderbilt University Medical Center and Augusta University—to determine how to improve participation from Black communities in lung cancer clinical trials.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
The National Comprehensive Cancer Network has published new best practice recommendations for Management of COVID-19 infection in patients with cancer.
A comprehensive review by University of North Carolina researchers and colleagues of hundreds of publications, incorporating more than two dozen articles on prevention screening for lung cancer with low-dose spiral computed tomography, shows there are both benefits and harms from screening.
JScreen, a national public health initiative based out of Emory University School of Medicine’s Department of Human Genetics, has established a program that offers at-home testing for more than 60 cancer susceptibility genes associated with hereditary risks for breast, ovarian, prostate, colorectal, skin and other cancers.
A John Hopkins study suggests gaining a better understanding of physical frailty could eventually help people age more healthfully.
The National Comprehensive Cancer Network has published NCCN Guidelines for Histiocytosis.
A study led by Yale Cancer Center and Department of Neurology researchers demonstrated that a blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma.
